Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: Are they valuable factors for therapeutic decision-making?

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 4, 2011, Pages 342-349

  Thomas, Xavier ^a   Chelghoum, Youcef ^a   Cannas, Giovanna ^a   Elhamri, Mohamed ^a   Labussière, Hélène ^a   Tigaud, Isabelle ^b   Ducastelle, Sophie ^a   Nicolini, Franck ^a   Dumontet, Charles ^a   Michallet, Mauricette ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Acute myeloid leukemia; Elderly; Hyperleukocytosis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICINE; MITOXANTRONE; UNCLASSIFIED DRUG; ANTHRACYCLINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; TREATMENT RESPONSE; BLOOD; CHROMOSOME ANALYSIS; COMORBIDITY; LEUKOCYTE; METABOLISM; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CYTARABINE; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; LEUKOCYTOSIS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84555206702     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.06.003     Document Type: Article

References (40)

1. SEER. Surveillance Epidemiology an End Results (SEER). SEER CANCER GOV[Web site]. Available at: www.seer.cancer.gov. Accessed: on August, 2005.
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481-5.
3. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with AML: analysis of 1, 065 patients entered into the MRC AML 11 trial. Blood 2001; 98:1312-20.
4. Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or AML) on outcome of AML-type chemotherapy. Blood 1997; 90:2969-77. (Pubitemid 27444190)
5. Goldstone AH, Burnett AK, Avivi I, et al. Secondary AML has a worse outcome than de novo AML even taking into account cytogenetics and age. AML 10, 11, 12 MRC trials. Blood 2002; 100 (suppl 1):88a.
6. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with AML: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479-85. (Pubitemid 38140076)
7. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in AML in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1302-11.
8. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with AML is not improved with mitoxantrone and eto-poside compared to daunorubicin and cytarabine: a Southwest Oncology Group Study. Blood 2002; 100:3869-76. (Pubitemid 35396851)
9. Van der Holt B, Löwenberg B, Burnett AK, et al. The value of MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated AML in relation to MDR1 status at diagnosis. Blood 2005; 106:2646-54. (Pubitemid 41510736)
10. Estey EH, Thall PF, Giles FG, et al. Gemtuzumab ozogamycin with or without interleukin 11 in patients 65 years of age or older with untreated AML or high-risk MDS: comparison with idarubicin plus high-dose continuous infusion cytosine arabinoside. Blood 2002; 99:4343-9. (Pubitemid 34627199)
11. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896-903. (Pubitemid 24299870)
12. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98:548-53.
13. Satariano WA, Silliman RA. Comorbidity: implications for research and practice in geriatric oncology. Crit Rev Oncol Hematol 2003; 48:239-48. (Pubitemid 37357304)
14. Dale DC. Poor prognosis in elderly patients with cancer: the role of bias and un-dertreatment. J Support Oncol 2003; 1:11-7.
15. Tilly H, Castaigne S, Bordessoulle D, et al. Low dose cytarabine vs. intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8:272-9. (Pubitemid 20056558)
16. Löwenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7:1268-74. (Pubitemid 19220128)
17. Plesa C, Le QH, Chelghoum Y, et al. Prognostic index for older adult patients with newly diagnosed acute myeloid leukemia: the Edouard Herriot Hospital experience. Clinical Leukemia 2008; 2:198-204.
18. Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008; 93:1806-13.
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83. (Pubitemid 17055592)
20. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-9. (Pubitemid 41510773)
21. Van der Holt B, Breems DA, Berna Beverloo H, et al. Various distinctive cytoge-netic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol 2007; 136:96-105. (Pubitemid 44912593)
22. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33:451-8.
23. Löwenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90:2952-61.
24. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group. J Clin Oncol 1998; 16:872-81. (Pubitemid 28115455)
25. Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999; 13:843-9. (Pubitemid 29292132)
26. Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106:27-34. (Pubitemid 40967170)
27. Gardin C, Turlure P, Fagot T, et al. Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy-results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109:5129-35. (Pubitemid 46900774)
28. Thomas X, Suciu S, Rio B, et al. Autologous stem cell trasplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 2007; 92:389-96. (Pubitemid 350143549)
29. Mitelman F. ICSN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
30. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642-9. (Pubitemid 46594039)
31. Wilson CS, Davidson GS, Martin SB, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006; 108:685-96. (Pubitemid 44061371)
32. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-18. (Pubitemid 351620111)
33. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:562-9.
34. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance inolder AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107:7473-8.
35. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine mono-therapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28:549-55.
36. Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhy-drazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007; 25:25-31. (Pubitemid 350003047)
37. Schiller GJ, O'Brien SM, Pigneux A, et al. Single-agent laromustine, a novel alky-lating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol 2010; 28:815-21.
38. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28:2389-95.
39. Giles F, Vey N, DeAngelo D, et al. Phase 3 randomised, placebo controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood 2009; 114:4027-33.
40. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638-45.